P3 Health Partners Sees $120M-$170M EBITDA Improvement Opportunity for 2026 Amid Payer Contract Enhancements.

P3 Health Partners Inc. (PIII) is expecting a $120M-$170M EBITDA improvement for 2026, driven by its $130M EBITDA improvement plan. The company's core business is showing positive momentum, with CEO Aric Coffman stating that it is nearing full execution. The company is also strengthening payer contracts.

P3 Health Partners Inc. (PIII), a patient-centered and physician-led population health management company, is expecting a significant EBITDA improvement for 2026. The company's core business is demonstrating strength, with CEO Aric Coffman indicating that it is nearing full execution of its $130M EBITDA improvement plan [1].

The second quarter of 2025 saw P3 managing medical cost trends to remain flat while improving funding across its membership on a per-member basis. Despite a 6% decline in total revenue due to a 9% decrease in membership, the company has identified an additional $120 to $170 million in EBITDA opportunities for 2026 [1].

P3's adjusted EBITDA loss for the second quarter was $8.5 million, or $25 PMPM, after excluding prior-period adjustments. The company's adjusted full year guidance reflects the impact from prior-period adjustments and the underperformance of a single payer [1].

The company's strategy to strengthen payer contracts and improve funding per member is showing positive results. With three of its four markets already EBITDA positive or breakeven, P3 is well-positioned to achieve sustained profitability in 2026 and beyond [1].

P3 will host a conference call and webcast on August 14, 2025, at 4:30 PM ET to discuss its second quarter 2025 earnings. Investors are encouraged to read the "Cautionary Note Regarding Forward-Looking Statements" included in the press release [1].

References:
[1] https://www.stocktitan.net/news/PIII/p3-health-partners-announces-second-quarter-2025-8bxzpgf3sceo.html